Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma

Inclusion Criteria:

• Target population must have relapsed, progressive or refractory non-hodgkin lymphomaand be ineligible for or have exhausted standard therapeutic options that mayprolong survival

• The subject must have fluoro-deoxyglucose (FDG)-avid lymphoma with measurabledisease

• CD38 positive tumor at most recent biopsy (new or archival) documented at centrallaboratory

• Subject must have an Eastern Cooperative Oncology Group (ECOG) performance statusscore of 0, 1, or 2

• Each subject must sign an ICF indicating that he or she understands the purpose of,and procedures required for the trial and is willing to participate in the trial.

Exclusion Criteria:

• Primary central nervous system lymphoma or known central nervous system involvementwith lymphoma

• Systemic chemotherapy, radiotherapy, immunotherapy, or major surgery administeredwithin 3 weeks (for nitrosoureas within 6 weeks) prior to the first dose ofCD38-SADA

• Radioimmunotherapy within 100 days prior to the first dose of CD38-SADA

• Autologous stem cell transplantation within 42 days prior to the first dose ofCD38-SADA

• Treatment with approved CAR-T within 100 days prior to the first dose of CD38-SADA

• >40% lymphoma bone marrow involvement